We can’t show the full text here under this license. Use the link below to read it at the source.
Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apnea
Armodafinil improves alertness and long-term memory in sleep apnea patients who use CPAP
AI simplified
Abstract
Armodafinil increased mean sleep latency by 2.0 minutes in patients with associated with obstructive sleep apnea.
- Patients receiving armodafinil showed a significant improvement in quality of episodic secondary memory compared to those on placebo.
- Armodafinil enhanced patients' ability to engage in activities of daily living compared to the placebo group.
- Fatigue levels decreased significantly in patients taking armodafinil compared to those on placebo.
- Common adverse events included headache, nausea, and insomnia, but armodafinil did not negatively impact nighttime sleep.
- usage remained consistent at approximately 7 hours per night among patients during the study.
AI simplified
Key numbers
2.0 min
Increase in Sleep Latency
Mean change from baseline in sleep latency for armodafinil group.
4.8 to 3.6
Reduction in Global Fatigue
Global fatigue score change from baseline to final visit.
7.2 to 5.8
Reduction in Worst Fatigue
Worst fatigue score in the past 24 hours from baseline to final visit.